Marks' letter highlighted the danger of undermining trust in public health science, lamenting the recent spike in measles cases, with Texas experiencing the worst of it. He expressed dismay at the current trajectory of health policy management under Kennedy. The guidelines and leadership direction seem to be shifting away from evidence-based approaches, raising alarms among health professionals about the potential implications for public health.
Peter Marks was with the FDA since 2012 and has served as the director of the Center for Biologics Evaluation and Research since 2016. His resignation is effective April 5th, amidst growing concerns about misinformation in health policies.
The implications of this upheaval in leadership could reverberate through the FDA and wider public health landscape, as Kennedy's unproven treatments and views gain traction. The battle over science and public health continues as the country grapples with rising vaccine skepticism.
Peter Marks was with the FDA since 2012 and has served as the director of the Center for Biologics Evaluation and Research since 2016. His resignation is effective April 5th, amidst growing concerns about misinformation in health policies.
The implications of this upheaval in leadership could reverberate through the FDA and wider public health landscape, as Kennedy's unproven treatments and views gain traction. The battle over science and public health continues as the country grapples with rising vaccine skepticism.
